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Chinese Herbal Medicine for Infertility with Anovulation:
A Systematic Review
Li Tan, MMed,1,2 Yao Tong, PhD,2 Stephen Cho Wing Sze, PhD,2 Mei Xu, MMed(cand),1
Yang Shi, MMed(cand),1 Xin-yang Song, MMed,3 and Ting-ting Zhang, PhD1
Abstract
The aim of this systematic review is to assess the effectiveness and safety of Chinese herbal medicine (CHM) in
treatment of anovulation and infertility in women. Eight (8) databases were extensively retrieved. The Chinese
electronic databases included VIP Information, CMCC, and CNKI. The English electronic databases included
AMED, CINAHL, Cochrane Library, Embase, and MEDLINE. Randomized controlled trials using CHM as
intervention were included in the study selection. The quality of studies was assessed by the Jadad scale and the
criteria referred to Cochrane reviewers’ handbook. The efficacy of CHM treatment for infertility with anovu-
lation was evaluated by meta-analysis. There were 692 articles retrieved according to the search strategy, and
1659 participants were involved in the 15 studies that satisfied the selection criteria. All the included trials were
done in China. Meta-analysis indicated that CHM significantly increased the pregnancy rate (odds ratio [OR]
3.12, 95% confidence interval [CI] 2.50–3.88) and reduced the miscarriage rate (OR 0.2, 95% CI 0.10–0.41)
compared to clomiphene. In addition, CHM also increased the ovulation rate (OR 1.55, 95% CI 1.06–2.25) and
improved the cervical mucus score (OR 3.82, 95% CI 1.78–8.21) compared to clomiphene, while there were no
significant difference between CHM and clomiphene combined with other medicine. CHM is effective in treating
infertility with anovulation. Also, no significant adverse effects were identified for the use of CHM from the
studies included in this review. However, owing to the low quality of the studies investigated, more randomized
controlled trials are needed before evidence-based recommendation regarding the effectiveness and safety of
CHM in the management of infertility with anovulation can be provided.
Introduction
Infertility is defined as failure to achieve pregnancyduring 1 year of frequent, unprotected intercourse.1 In-
fertility affects about 10%–20% of couples trying to achieve
pregnancy in many industrialized countries,2 and there is an
increasing number of couples seeking medical treatment.3 A
study estimates that in 2002, more than 186 million ever-
married women of reproductive age in developing countries
were infertile.4
It is known that about 40% of infertility cases are due to
female factors. Ovulatory dysfunction will be identified
in approximately 15% of all infertile couples and accounts
for up to 40% of infertility in women.5 Ovulatory dys-
function is defined as abnormal, irregular, or absent
ovulation. Approximately 15%–-25% of patients with
ovulatory dysfunction are anovulatory,6 which can be at-
tributed to an imbalance of luteinizing hormone and
follicle-stimulating hormone, an injury to the hypothala-
mus or pituitary gland, pituitary tumors, or too low or too
high a body weight.7
Methods for evaluating ovulatory function may include:
menstrual history, basal body temperature (BBT), serum
progesterone, urinary luteinizing hormone, endometrial bi-
opsy, histologic evaluation, and serial transvaginal ultra-
sound.8–11
Hull reported that the most successful treatment is for
women with clearly defined ovulatory disorders.12 In most
women with ovulatory dysfunction without an evident
cause or that is not otherwise correctable, ovarian stimula-
tion is the primary treatment.13 Fertility drugs are often used
to induce ovulation. If they fail as the sole therapy, they may
be used with assisted reproductive procedures, such as
in vitro fertilization.14
1YueYang Hospital of Integrative Chinese & Western Medicine Affiliated with Shanghai University of Traditional Chinese Medicine,
Shang Hai, China.
2School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
3Shanghai University of Traditional Chinese Medicine, Shang Hai, China.
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
Volume 18, Number 12, 2012, pp. 1087–1100
ª Mary Ann Liebert, Inc.
DOI: 10.1089/acm.2011.0371
1087
Clomiphene citrate has been used as the first-line treat-
ment for inducing ovulation in anovulatory women.15,16 In
most women who fail to ovulate or conceive with clomi-
phene citrate, gonadotrophins bring about ovulation.17,18
Recent studies have reported that the aromatase inhibitor,
letrozole, is an attractive option.19 Because the cloud of im-
puted teratogenesis is difficult to dispel with finality, ar-
omatase inhibitors at present remain second-line agents.20
Ovulation-inducting agents have their own specific ad-
verse effects. Some, in particular those effects associated with
gonadotrophins, may be life threatening.21 In addition, in-
duction of ovulation has been shown to raise the risk of
miscarriage.22 With regard to the long-term safety of these
medications, the relationship between fertility drugs and
epithelial ovarian cancer is controversial.23–29 Assisted re-
productive technology is highly effective when it comes to
increasing conception, but most people cannot afford the
cost. It is often associated with many physical and emotional
side-effects, such as ovarian hyperstimulation syndrome
(OHSS), multiple births, and birth defects.30–33
For this reason, more couples are turning to alternative
medicine, especially Chinese herbal medicine (CHM).34–36
The use of herbal medicinal products is rapidly increasing.
Virtually all survey data agree that users of herbal medicine
products are predominantly female.37–39
Traditional Chinese medicine (TCM) is the world’s oldest
continuous surviving tradition, a 3000-year-old holistic sys-
tem for both treatment and prevention of disease. Records
indicate that Chinese medicinal herbs have a long history of
use in treating male and female infertility for more than 2000
years. Chinese medicine practitioners believe that anovula-
tion is mostly caused by deficiency of Kidney, Stasis of Liver
Qi (keep in mind that in Chinese Medicine, there is more to
an ‘‘organ’’ than its Western anatomical counterpart),
Phlegm Dampness, and Blood Stasis (they are a syndrome
identified by Chinese Medicine).40–42 In these cases, the aims
of TCM therapy are tonifying and replenishing Kidney Qi,
enriching and tonifying Kidney Yin, warming and tonifying
Kidney Yang, soothing the Liver and releasing depression,
drying Dampness, and resolving Phlegm, activating Blood,
and resolving Stasis.41–43
Herbs such as Radix rehmanniae, Radix Dipsaci, semen
cuscutae, Cistanches, Fructus Lycii, Radix Morindae Officinalis,
Epimedii, Cornu Cervi Degelatinatum, and Placenta Hominis are
used to tonify the Kidney; Radix Bupleuri, Radix Paeoniae Alba,
Fructus Aurantii, Rhizoma Cyperi, and Radix Curcumae are
used to sooth the Liver and release depression; Rhizoma
Atractylodis, Rhizoma Acori Tatarinowii, Pericarpium Citri Re-
ticulatae, Rhizoma Pinelliae, and Poria are used to dry Damp-
ness and resolve Phlegm; some herbs frequently used to
activate Blood and resolve Stasis are Radix Angelicae Sinensis,
Rhizoma Chuanxiong, Radix Paeoniae Rubra, Semen Persicae,
Flos Carthami, Radix Cyathulae, and Sanguis Draconis.41,43,44
TCM is traditionally regarded as having few side-effects. It
is therefore becoming increasingly popular with the public.
Recently, many clinical trials reported that CHM had a
positive effect in treating infertile women with ovulatory
dysfunction.45–50 However, most of the clinical trials were
based on a small sample size. As there is currently insuffi-
cient evidence about the safety and efficacy of CHM for the
management of infertility with anovulation, a systematic
review in this area is warranted.
Methods
Articles were retrieved from databases by electronic
search. Only articles that satisfied the selection criteria were
included in the meta-analysis. The articles were reviewed
independently by 2 reviewers. After selection, the data were
extracted by the first reviewer and verified by the second
reviewer. Discrepancies were rectified while referring to the
original articles.
Criteria for Considering Studies for This Review
Types of studies
Randomized controlled trials (RCTs) were included.
Quasi-RCTs, non-RCTs, or randomized trials with false
methods for random allocation of participants were ex-
cluded. Articles were written in either English or Chinese
language.
Types of participants
Female patients, of any age or ethnic origin, who were
incapable of conceiving for at least 1 year (includes primary
and secondary subfertility) as a result of anovulation, were
included in the study. Luteal phase defect, tubal disease,
immune infertility, and unexplained infertility were ex-
cluded. Sperm analysis of the partner should be normal.
The diagnostic criteria of anovulation employed in the
present review were based on the American Society of Re-
productive Medicine report,51 the standard drafted by the
Obstetrics and Gynecology Committee of The China Asso-
ciation of Integrative Medicine,52 and the guiding principle
issued by the Ministry of Health of the People’s Republic of
China.53
Anovulation was diagnosed if an individual had two or
more of the following six criteria: (1) Monophasic BBT re-
cordings lasted for more than 3 months, (2) Serum or urine
progesterone levels that fell below the normal values during
the midluteal phase, (3) Endometrial biopsy and histologic
evaluation that demonstrated no secretory endometrial de-
velopment during the late luteal phase (6 days before men-
struation), (4) Transvaginal ultrasound reveal no evidence of
ovulation, (5) Vaginal cytology smears showing no cyclical
changes, or (6) Cervical mucus crystallization that occurred
without ellipsoid.
Ideally, the diagnostic criteria of anovulation should be
stated and described in the trial that was searched for this
review. If the criteria were not employed in the searched
trials, the stated diagnostic criteria in each individual study
were evaluated by the review authors to confirm whether it
met above the criteria. Trials with inconsistent diagnostic
criteria were excluded. If the diagnostic criteria were not
clearly stated in the trial, the primary authors were contacted
for clarification. In case clarification was unavailable, these
trials were also excluded.
Types of Interventions
Experimental interventions encompassed Chinese patent
herbal medicine, extracts of a single herb or compound of
herbs, or other individualized herbal remedies. Control in-
terventions comprised placebo, no treatment, Western med-
icine, and laparoscopic surgery.
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Types of Outcome Measures
Primary outcomes include live birth rate, pregnancy rate,
and ovulation rate. Secondary outcomes include the change
of BBT, cervical mucus score, endometrial thickness, follicle
growth, miscarriage, ectopic pregnancy and adverse events
(including OHSS, luteinized unruptured follicle syndrome
(LUFS), multiple pregnancy, gastrointestinal reactions,
headaches, general malaise, etc.).
Search Strategy
The terms retrieved in databases were infertile, infertility,
sterile, sterility, anovulation, anovulatory, ovulatory dysfunc-
tion, ovulatory disorders, ovulation failure, ovarian Stimulation,
ovarian Induction, Chinese traditional, Chinese medicine, al-
ternative medicine, Complementary Therap$, chinese herbal,
Plants, plant extract$, herb$. The combined search was (infertile
OR infertility OR steril OR sterility) AND (anovulation OR
anovulatory OR ovulatory dysfunction OR ovulatory disorders
OR ovulation failure OR ovarian Stimulation OR Ovarian In-
duction) AND (Chinese traditional OR Chinese medicine OR
alternative medicine OR Complementary Therap$ OR chinese
herbal OR Plants OR plant extract$ OR herb$). Chinese lan-
guage databases were retrieved with a similar search strategy.
Databases
A total of eight databases were extensively searched. The
Chinese electronic databases included VIP Information (1989–
2011.3), CMCC (1994–2011.3), and CNKI (1979–2011.3). The
English electronic databases included AMED (1985–2011.3),
CINAHL (1982–2011.3), Cochrane Library (1993–2011.3),
Embase (1996–2011.3) and MEDLINE (1966–2011.3).
Data Analysis
The Review Manager 4.2 software developed at the Nor-
dic Cochrane Centre was employed for data analysis. Di-
chotomous data were presented as odds ratio (OR) and
continuous outcomes as mean difference, both with 95%
confidence intervals (CI). Differences were considered sta-
tistically significant, and p-value was < 0.05.
Results
Study selection
The initial searches identified 692 articles on treatment
with TCM for infertile women with ovulatory dysfunction.
On reading titles and abstracts, it was found that 626 of these
articles were excluded because they were duplicates, non-
clinical studies, case reports, or had study objectives different
from this review. A total of 66 articles published in Chinese
were retrieved for further assessment. Of these, 51 articles
were excluded because they did not meet the inclusion cri-
teria of this review. In total, 15 articles that satisfied the se-
lection criteria were included.54–68
Methodological quality of included studies
There were 1659 participants who enrolled in 15 studies.
Sample size ranged from 46 to 335. Nine hundred and
eighty-two (982) were allocated to the treatment group and
677 were allocated to the control group. All participants were
women of reproductive age, but with infertility and anovu-
lation. All clinical studies were conducted in China and re-
ported in the Chinese language. Though the clinical trials
claimed randomization in their studies, all of these trials
were marked as high-risk bias due to the unclear allocation
concealment, blindness, and withdrawal/dropout. All stud-
ies were classified according to the Jadad scale,69 as shown in
Table 1.
Study characteristics
Periodic therapies by using different CHM were applied in
four studies. Chinese patent drugs were used in six studies.
Table 1. Quality Evaluation of Included Studies
Quality Assessment
Study Treatment (N) Control (N) Ran. All Con Blind With/drop TS JSS
Cui et al. (2003) 120 80 A C C C HRB 2
Huang et al. (2006) 90 45 A C C C HRB 2
Liu (2010) 30 30 A C C C HRB 2
Huang (2007) 32 20 A C C C HRB 2
Qiu Fen-lian et al. (2004) 25 21 B C C C HRB 1
Pang et al. (1997) 59 53 B C C C HRB 1
Xu (2009) 30 30 B C C C HRB 1
Qiu Ming-ying et al. (2004) 30 30 B C C C HRB 1
Luo et al. (2007) 182 153 B C C C HRB 1
Chu et al. 2006 60 60 B C C C HRB 1
Yin et al. (2006) 120 40 B C C C HRB 1
Yin et al. (2004) 76 32 B C C C HRB 1
Xia et al. (2004) 45 23 B C C C HRB 1
Fu (2007) 34 20 B C C C HRB 1
Huang (2002) 49 40 B C C C HRB 1
Subtotal 982 677
Total 1659
Ran, randomization; All Con, allocation concealment; Blind, blindness; With/drop, withdrawal/dropout; A, adequate; B, inadequate; C,
unclear; HRB, high-risk bias; TS, total score; JSS, Jadad scale score.
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Chinese herbal formulas were used in five studies. Details
are listed in Table 2.
There were 13 studies used clomiphene only as the con-
trols; 4 of them used clomiphene from 50 mg/d to 100 mg/d
or 150 mg/d when no ovulation occurred in the first two
cycles. For the other two studies, Qiu Ming-ying et al. (2004)
used clomiphene combined with diethylstilbestrol and me-
droxyprogesterone as the controls, and Fu (2007) selected
clomiphene combined with human chorionic gonadotrophin
as the controls.
The duration of trials selected in this study varied from 3
months to 6 months, yet the duration recorded in one article
was 1 month67 while another article did not report the trial
duration.59 All articles have reported the diagnostic criteria
used, with all participants diagnosed with infertility and
anovulation in these studies.
Pregnancy rate (per woman) was reported in all studies.
Ovulation rate (per woman) was reported in 13 studies. The
change of BBT was reported in five studies. Improvement of
cervical mucus score was reported in two studies. Change of
endometrial thickness was reported in three studies. Follicle
growth was reported in six studies. Adverse events were
reported in four studies. Live birth rate (per woman) was not
measured by any included studies (Table 3).
Effects and adverse events of interventions
There were 13 trials (1545 women) that compared one of the
commonly used CHM with clomiphene, and two trials (114
women) that compared CHM with combination therapy. Sub-
groups were set up for statistical analysis based on the type of
CHM used and different combination therapy as control.
Pregnancy rate
CHM versus clomiphene (see Analysis 1.1). There were
13 trials (1545 women) that reported statistically significant
difference between CHM and clomiphene (58.50% versus
30.46%; OR 3.12, 95% CI 2.50–3.88). This meta-analysis in-
cluded four trials (615 women) compared periodic therapies
to clomiphene (60.50% versus 33.20%; OR 2.95, 95% CI 2.09–
4.17); four trials (501 women) compared Chinese patent
drugs to clomiphene (64.07% versus 29.61%; OR 4.20, 95% CI
2.86–6.17); the other five trials (429 women) compared Chi-
nese herbal formulas to clomiphene (49.43% versus 27.38%;
OR 2.36, 95% CI 1.55–3.61).
CHM versus clomiphene combination therapy (see Ana-
lysis 2.1). There were two trials (114 women) that reported
no statistically significant difference between CHM and
combination therapy (51.56% versus 34%; OR 2.12, 95% CI
0.98– 4.57). This meta-analysis included one trial (60 women)
that compared CHM to clomiphene combined with diethyl-
stilbestrol and medroxyprogesterone (56.67% versus 33.33%;
OR 2.62, 95% CI 0.92–7.46); the other trial (54 women)
compared CHM to clomiphene combined with human
chorionic gonadotrophin (47.06% versus 35%; OR 1.65, 95%
CI 0.53–5.16).
Table 2. Contents of the Formulations Used in Included Studies
Cui et al. (2003) Homemade Chinese
patent drug
Basic formula of zhu yun pill No. 1, which was produced by
their hospital’s Preparation room.
Huang et al. (2006) Homemade Chinese
patent drug
Basic formula of an kun zhong zi pill, which was produced
by their hospital’s Preparation room.
Liu (2010) Periodic therapies 1. Basic formula of cu pai luan decoction No. 1 for late follicular
phase from the 5th to 12th day of menstrual cycle; 2. Basic
formula of cu pai luan decoction No. 2 for ovulation phase
and luteinizing phase from the 13th to 22nd day of
menstrual cycle.
Huang (2007) Herbal formula Basic formula of bu shen hua yu decoction.
Qiu Fen-lian
et al. (2004)
Chinese patent drug Basic formula of tiao jing cu yun pill, which had national
drug production batch number.
Pang et al. (1997) Herbal formula Basic formula of bu shen zhong zi pellet.
Xu (2009) Periodic therapies 1. Basic formula of wu zi yan zong decoction for follicular phase;
2. Basic formula of cu pai luan decoction for ovulation phase;
3. Basic formula of cu huang ti decoction for luteinizing phase.
Qiu Ming-ying
et al. (2004)
Chinese patent drug Basic formula of gui lu bu shen pill, which had national drug
production batch number.
Luo et al. (2007) Periodic therapies 1. Basic formula of tiao jing decoction No. 1 for follicular phase;
2. Basic formula of tiao jing decoction No. 2 for ovulation phase;
3. Basic formula of tiao jing decoction No. 3 for luteinizing phase;
4. Basic formula of tiao jing decoction No. 4 for menstrual phase.
Chu et al. (2006) Homemade Chinese
patent drug
Basic formula of er zi capsule, which was produced by their
hospital’s Preparation room.
Yin et al. (2006) Periodic therapies 1. Basic formula of bu shen tian jing decoction; 2. Basic formula
of tao hong si wu decoction.
Yin et al. (2004) Herbal formula Basic formula of shuang zi decoction.
Xia et al. (2004) Herbal formula Basic formula of nv zhen yun yu decoction.
Fu (2007) Homemade Chinese
patent drug
Basic formula of zhu yun pill, which was produced by their
hospital’s Preparation room.
Huang (2002) Herbal formula Basic formula: The experimental formula for nourishing
Kidney Yin and Blood.
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Table 3. Characteristics of Included Studies
Study Intervention Controlled intervention Duration Outcome measurement
Cui et al. (2003) Homemade Chinese
patent drug
Clomiphene 50 mg/d 6 months Pregnancy rate, ovulation rate,
BBT, adverse events
Huang et al.
(2006)
Homemade Chinese
patent drug
Clomiphene 50 mg/d 6 months Pregnancy rate, ovulation rate,
BBT, cervical mucus score,
follicle growth
Liu (2010) Periodic therapies Clomiphene 50 mg/d 3 months Pregnancy rate, ovulation rate
Huang (2007) Herbal formula Clomiphene 50 mg/d 6 months Pregnancy rate, ovulation rate
Qiu Fen-lian
et al. (2004)
Chinese patent drug Clomiphene 50–100 mg/d 3 months Pregnancy rate, ovulation rate,
adverse events
Pang et al. (1997) Herbal formula Clomiphene 50–100 mg/d Not mentioned Pregnancy rate
Xu (2009) Periodic therapies Clomiphene 50 mg/d 3 months Pregnancy rate, ovulation rate
Qiu Ming-ying
et al. (2004)
Chinese patent drug Clomiphene 50 mg/d
Diethylstilbestrol 0.25 mg/d
Medroxyprogesterone 1 mg/d
3–6 months Pregnancy rate, ovulation rate,
endometrial thickness,
follicle growth
Luo et al. (2007) Periodic therapies Clomiphene 50 mg/d 3 months Pregnancy rate, ovulation rate,
BBT, adverse events
chu et al. 2006 Homemade Chinese
patent drug
Clomiphene 50 mg/d 3 months Pregnancy rate, ovulation rate,
BBT, follicle growth, adverse
events
Yin et al. (2006) Periodic therapies Clomiphene 50 mg/d 6–9 months Pregnancy rate, ovulation rate,
follicle growth
Yin et al. (2004) Herbal formula Clomiphene 50 mg/d 3–6 months Pregnancy rate, ovulation rate,
follicle growth
Xia et al. (2004) Herbal formula Clomiphene 50–100 mg/d 3 months Pregnancy rate, ovulation rate,
endometrial thickness, follicle
growth, adverse events
Fu (2007) Homemade Chinese
patent drug
Clomiphene 50 mg/d
HCG 5000–10,000 U
1 month Pregnancy rate, BBT, cervical
mucus score, endometrial
thickness
Huang (2002) Herbal formula Clomiphene 50–100 mg/d 6 months Pregnancy rate, ovulation rate
BBT, basal body temperature; HCG, human chorionic gonadotropin.
ANALYSIS 1.1. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 1: pregnancy rate (per
woman).
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Ovulation rate
CHM versus clomiphene (see Analysis 1.2). There were
11 trials (1365 women) that compared CHM with clomiphene.
Four trials (615 women) reported no statistically significant
difference between periodic therapies and clomiphene (73.20%
versus 62.45%; OR 1.7, 95% CI 0.87–3.32). Four (4) trials (501
women) reported no statistically significant difference be-
tween Chinese patent drugs and clomiphene (79.32% versus
69.90%; OR 1.53, 95% CI 0.72–3.26). The other three trials (249
women) reported no statistically significant difference be-
tween Chinese herbal formulas and clomiphene (84.71% ver-
sus 81.52%; OR 1.32, 95% CI 0.64–2.71).
Overall, meta-analysis of 11 trials (1365 women) showed
that there was a statistically significant difference between
CHM and clomiphene (78.81% versus 69.69%; OR 1.55, 95%
CI 1.06–2.25).
CHM versus clomiphene combination therapy (see Ana-
lysis 2.2). One (1) trial (60 women) compared CHM to
clomiphene combined with diethylstilbestrol and medroxy-
ANALYSIS 2.1. Comparison 2. Chinese herbal medicine (CHM) versus clomiphene combination therapy, outcome 1
pregnancy rate.
ANALYSIS 1.2. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 2: ovulation rate (per woman).
1092 TAN ET AL.
progesterone. The difference shown was not statistically
significant (70% versus 73.33%; OR 0.85, 95% CI 0.28–2.61).
BBT becoming biphasic
CHM versus clomiphene (see Analysis 1.3). Three (3)
trials (596 women) reported this outcome, one as typical
biphasic BBT62 and another two as atypical and typical
biphasic BBT.55,63 We used the typical biphasic BBT as
outcome for final comparison.
Meta-analysis of three trials (596 women) showed that
there was no statistically significant difference between CHM
and clomiphene (65.78% versus 64.59%; OR 1.06, 95% CI
0.73–1.53).
ANALYSIS 2.2. Comparison 2. Chinese herbal medicine (CHM) versus clomiphene combination therapy, outcome 2
ovulation rate (per woman).
ANALYSIS 1.3. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 3: basal body temperature
becoming biphasic.
ANALYSIS 2.3. Comparison 2. Chinese herbal medicine (CHM) versus clomiphene combination therapy, outcome 3 basal
body temperature becoming biphasic.
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CHM versus clomiphene combination therapy (see Ana-
lysis 2.3). One (1) trial (54 women) compared CHM to
clomiphene combined with chorionic gonadotrophin. The
difference showed there was not a statistically significant
difference (55.88% versus 45%; OR 1.55, 95% CI 0.51–4.70).
Improvement of cervical mucus score
CHM versus clomiphene (see Analysis 1.4). One (1) trial
(130 women) compared CHM against clomiphene.55 Results
showed that CHM was significantly more effective for im-
proving cervical mucus score than clomiphene was (68.60%
versus 36.36%; OR 3.82, 95% CI 1.78–8.21).
CHM versus clomiphene combination therapy (see Ana-
lysis 2.4). One (1) trial (54 women) compared CHM against
combination therapy.67 Results showed that CHM was not
significantly more effective for improving cervical mucus
score than clomiphene combined with human chorionic go-
nadotrophin (weighted mean difference [WMD] 0.70, 95%
CI - 0.59–1.99).
Change of endometrial thickness
CHM versus clomiphene. One (1) trial,66 which only re-
ported the average thickness of two groups (no standard
deviation), showed a significant increase in thickness after
treatment in the treated group, but no significant difference
in the control group.
CHM versus clomiphene combination therapy (see Ana-
lysis 2.5). There were two trials (114 women) that reported
no statistically significant difference between CHM and
combination therapy (WMD 0.39, 95% CI - 0.15–0.94).
Follicle growth
CHM versus clomiphene (see Analysis 1.6). There were
five trials that compared CHM with clomiphene. One (1)
trial66 only reported the average size of two groups. There
were no standard deviations provided, so it was not in-
cluded in meta-analysis.
Four trials (523 women) reported that this outcome was
included in meta-analysis, one trial (160 women) used peri-
odic therapies,64 another two trials (255 women) used Chi-
nese patent drugs,55,63 and another trial (108 women) used
Chinese herbal formulas.64
Meta-analysis of four trials (523 women) showed that
there was no statistically significant difference between CHM
and clomiphene (WMD - 0.37 95% CI - 2.12–1.38).
CHM versus clomiphene combination therapy (see Ana-
lysis 2.6). One (1) trial (60 women) compared CHM to
clomiphene combined with diethylstilbestrol and medrox-
yprogesterone. The difference showed no statistically sig-
nificant difference (WMD - 0.75 95% CI - 1.66–0.16).
Miscarriage rate (see Analysis 1.7)
There were three trials (938 women in trial, 307 women
were pregnant) that reported a statistically significant dif-
ference between CHM and clomiphene (6.01% versus
27.47%; OR 0.2, 95% CI 0.10–0.41). This meta-analysis in-
cluded one trial (170 women were pregnant) that compared
ANALYSIS 1.4. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 4: the improvement of cer-
vical mucus score.
ANALYSIS 2.4. Comparison 2. Chinese herbal medicine (CHM) versus clomiphene combination therapy, outcome 4 the
improvement of cervical mucus score.
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periodic therapies to clomiphene (9.91% versus 32.2%; OR
0.23,95% CI 0.10–0.53); one trial (100 women were preg-
nant) compared Chinese patent drugs to clomiphene (0%
versus 20%; OR 0.02, 95% CI 0.00–0.44); the other trial
(37 women were pregnant) compared Chinese herbal for-
mulas to clomiphene (8% versus 16.67%; OR 0.43, 95% CI
0.05–3.44).
Ectopic pregnancy (see Analysis 1.8)
One (1) trial (335 women in trial, 170 women were preg-
nant) reported no statistically significant difference between
CHM (periodic therapies) and clomiphene (1.8% versus
8.47%; OR 0.2, 95% CI 0.4–1.05).
Adverse events
OHSS (see Analysis 1.9). Only one study (335 women)
reported OHSS. There was no statistically significant differ-
ence between CHM (periodic therapies) and clomiphene for
OHSS (0% versus 6.54%; OR 0.28, 95% CI 0.01–6.89).64
LUFS (see Analysis 1.10). Only one study (335 women)
reported LUFS. There was a statistically significant difference
ANALYSIS 2.6. Comparison 2. Chinese herbal medicine (CHM) versus clomiphene combination therapy, outcome 6 follicle
growth.
ANALYSIS 1.6. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 6: follicle growth.
ANALYSIS 2.5. Comparison 2. Chinese herbal medicine (CHM) versus clomiphene combination therapy, outcome 5 the
change of endometrial thickness.
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ANALYSIS 1.9. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 9: adverse events, ovarian
hyperstimulation syndrome (OHSS Chinese herbal medicine).
ANALYSIS 1.7. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 7: miscarriage rate.
ANALYSIS 1.8. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 8: ectopic pregnancy.
ANALYSIS 1.10. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 10: adverse events, lutei-
nized unruptured follicle syndrome (LUFS).
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between CHM (periodic therapies) and clomiphene for LUFS
(6.59% versus 19.61%; OR 0.29, 95% CI 0.14–0.59).64
Multiple pregnancy (see Analysis 1.11). Only one study
(200 women in trial, 100 women were pregnant) reported
multiple pregnancy. There was no statistically significant
difference between CHM (periodic therapies) and clomi-
phene for multiple pregnancy (0% versus 4%; OR 0.08, 95%
CI 0.00–2.06).54
Other no serious adverse events (see Analysis
1.12). Two (2) trials (166 women) reported no serious ad-
verse events (including tiredness, dizziness, headache, pal-
pitations, nausea, vomiting, diarrhea, dry mouth,
drowsiness, abnormal uterine bleeding, urticaria, atopic
dermatitis, breast pain, and weight gain) in either the treated
or control groups. Meta-analysis of two trials (166 women)
showed that there was no statistically significant difference
between CHM (Chinese patent drugs) and clomiphene
(4.71% versus 29.63%; OR 0.09, 95% CI 0.00–1.67).58,63
Live birth rate
This outcome index was not reported in any of the in-
cluded studies.
Discussion
The aim of this review was to assess the effectiveness of
CHM and its safety for the treatment of anovulation and
infertility in women. CHM has been used to treat conditions
in female patients for more than 2000 years. However, there
is a dearth data on the administration of CHM in a rigorous
scientific context.
The review included 15 trials, which furnished promising
evidence in the form of RCTs for the use of CHM in in-
creasing pregnancy rate and ovulation rate, improving cer-
vical mucus score, reducing miscarriage rate in the treatment
of infertility with anovulation, but did not present other
evidence of any other effects. Live birth rate, as the most
important outcome for infertile patients, is unclear for CHM
in treating women with anovulation and infertility. No sig-
nificant adverse effects were identified for the use of CHM
from the included studies in this review.
Impact of Individualized Approaches of CHM
Traditional treatment with CHM needs to be tailored ac-
cording to different patterns, according to a description of
symptoms and signs attributed to different syndromes.
Moreover, a pattern has individual variations and changes
over time with different stages of disease. In CHM, treatment
differs according to the identified and diagnosed syndrome.
Six of 15 included trials considered an inclusion criterion
in relation to the TCM diagnostic syndrome (all were the
syndrome of deficiency of the Kidney), and another 9 trials
considered only Western diagnostic criteria. In other words,
the minority of included trials paid special attention to the
role of differentiated syndrome defined in TCM diagnosis for
infertility, because the syndrome of infertility in TCM in-
forms the selection of treatment formulation. The syndrome
of Deficiency of the Kidney was the common diagnostic
classification of infertility in TCM diagnosis.70–73 This was in
agreement with the majority of published diagnostic proto-
cols in TCM. The selection of CHM used in the trials in
this review was mostly influenced by the TCM diagnostic
process.
ANALYSIS 1.12. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 12 adverse events: other not
serious adverse events.
ANALYSIS 1.11. Comparison 1. Chinese herbal medicine (CHM) versus clomiphene, outcome 11 adverse events: multiple
pregnancy.
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Some trials used periodic therapies in accordance with the
individual syndromes and different stages. Some trials used
Chinese patent drugs and Chinese herbal formulas across the
whole period of clinical intervention, either because one di-
agnostic syndrome of infertility was selected for this specific
patent drug or formula, or simply because no consideration
was given to the possible variation of diagnostic syndromes.
Therefore, this review was unable to provide an explicit
answer as to whether periodic therapies were more beneficial
than Chinese patent drugs or Chinese herbal formulas in the
treatment of infertility with anovulation.
Adverse Effects
Although one study reported a statistically significant
difference between CHM and clomiphene for LUFS, the
safety of CHM in clinical practice was not addressed ade-
quately in the reviewed trials. The measurement and report
of adverse effects were poor; most trials neglected the fact
that herbs are not risk free. Only three trials mentioned some
adverse effects and detailed the number of incidents, not
only in the treated groups but also in the control groups. This
allowed appropriate data to be extracted for meta-analysis.
Generally, the reviewed trials reported that use of CHM for
treatment of infertility with anovulation was safe when
compared with ovulation-induction agents (clomiphene).
Adverse events including LUFS, OHSS and multiple preg-
nancy have been reported in only one study, but without
reporting of the severity. Other adverse events occasionally
induced by CHM are not reported comprehensively, such as
impairment of liver and kidney, and allergy. More trials that
monitor possible adverse effects are needed.
Quality of the Evidence
Jadad scores of the 15 RCTs were 1–2, which means that
the methodological quality of these RCTs was of a poor
caliber. Except for randomization methods, no trial clearly
described their methods of allocation concealment, blind-
ness, or withdrawal/dropout.
Another weakness was the small sample size. Half of the
trials had less than 100 participants. The small size reduces
the likelihood of detecting the effect of an intervention in a
single study, but given the similarities between studies, it
makes meta-analysis of the data particularly valuable.
The lack of placebo trials affects the results, since typically
a medicine’s efficacy is established with placebo trials before
comparisons are made with other drugs. In addition, the lack
of blinding in these trials might affect the results as it may
give skewed results, if participants were aware of their
treatment.
A possible publication bias has not been excluded in this
review, because the majority of trials reported positive effects
of CHM in the treatment of infertility. Funnel plots were
used to investigate the possibility of publication bias, for the
trials comparing CHM with clomiphene. For the outcomes of
pregnancy rate, the funnel plots appeared roughly symmet-
rical, indicating less chances of publication bias in this group
of trials (Fig. 1).
Overall, this review has found that an attempt toward
evidence-based TCM practice has been made. However,
good design of multicentered, randomized, parallel-con-
trolled and blinding trials is needed before undertaking
further studies, with the aim of providing better evidence-
based medicine evidence.
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